Coty Shares Surge on Report Company Looking to Sell Off Units
Shares of Coty Inc. jumped following a report the embattled cosmetics and perfume company is contemplating splitting up the business.
The stock rose as much as 13% after Women's Wear Daily said the company is in the early stages of a sale process, citing 'multiple industry sources' it didn't identify.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Washington Post
33 minutes ago
- Washington Post
US and UK say they've cemented a trade agreement that Trump calls fair for both nations
BANFF, Alberta — President Donald Trump and Prime Minister Keir Starmer said Monday that they are signing a trade deal that will slash tariffs on goods from both countries. The deal does not include tariffs on steel, an especially important piece of bilateral trade. Instead, talks are still going on about whether steel tariffs will be cut to zero as planned in the provisional agreement.
Washington Post
33 minutes ago
- Washington Post
Biotech pauses trial after second patient death linked to gene therapy
Biotech firm Sarepta Therapeutics said that a second patient died after receiving its gene therapy to treat Duchenne muscular dystrophy, the latest drug to draw scrutiny after winning fast regulatory approval. The Cambridge, Massachusetts-based firm's stock lost more than 40 percent of its value Monday, a day after disclosing the death and announcing that it would temporarily stop shipping the treatments for certain patients, and pause a clinical trial, while it evaluates its protocols.
Fast Company
34 minutes ago
- Fast Company
Eli Lilly is making it cheaper and easier to buy high-doses of blockbuster weight loss drug Zepbound
Eli Lilly announced on Monday it will soon make the two highest-doses of its popular weight-loss drug Zepbound available for self-paying customers on its website. Starting in August, 12.5 mg and 15 mg single-doses will be added to the company's website, effectively making all Zepbound doses available for $499 a month, or less. Unlike the pen form sold at pharamcies like Walgreens and CVS, the drug will be available in vial form through its LillyDirect self-pay pharmacy, which will require patients to draw their own shots into a syringe rather than have them prefilled. The drug will be to any eligible adult with obesity and a valid prescription regardless of insurance coverage. Health care providers and doctors can start prescribing the higher doses on July 7, according to Lilly. Zepbound is an injectable prescription medicine that belongs to a class of drugs known as GLP-1 receptor agonists originally developed for type 2 diabetes, that may help adults for treating obesity and weight-related medical issues. 'Obesity is a serious, chronic disease, and access to obesity medications should be treated with the same urgency as other chronic conditions,' Rhonda Pacheco, group vice president of U.S. Cardiometabolic Health at Lilly said in the press release. 'Lilly was the first company to offer a self-pay solution for an FDA-approved obesity medication, and we continue to work to expand coverage for Zepbound. In the meantime, the availability of the two highest-dose Zepbound vials gives providers and patients another important treatment option.' While the weight-loss drugs are popular with consumers, not so much with insurance companies, who don't always widely cover the drugs, leading Lily, and rival Novo Nordisk, the maker of Wegovy, to start offering their own self-pay options. The company first rolled out its self-pay, single-dose vials last summer in an effort to meet high consumer demand. Shares in the (NYSE: LLY) were trading down less than 2% at the market's close on Monday. Eli Lily: By the numbers In Eli Lily's latest round of earnings for the first quarter of 2025, ending March 31, 2025, the company showed a mixed performance, and reported net income of $2.76 billion and earnings per share (EPS) of $3.34, with revenue guidance between $58 billion and $61 billion. The drug maker has a market capitalization of $724.99 billion, as of this writing.
